Opinion
The Highland County Press1hOpinion
Follow the science: Why he was asked to leave the FDA
Dr. Marks was asked to leave and then subsequently wrote that he did not want to become “subservient to [Secretary Kennedy’s] misinformation and lies.” Peter Marks is not a hero of the resistance but ...
Fierce Pharma2h
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
The Print5h
Parents of muscular dystrophic patients protest in Delhi, demand access to high-cost treatment
Over 200 parents from 26 states across India protested at Jantar Mantar on Wednesday with their children affected by Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophy (MD), demanding urgent ...
Managed Healthcare Executive9h
New Study Shows Duchenne's Effect on the Brain Might Be Reversed
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Sarepta upgraded to Neutral from Sell at H.C. Wainwright
H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current ...
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to “Sector Perform” at Royal Bank of Canada
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...